Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special drug-use surveillance of Kesimpta in Japanese MS patients
jRCT2031210175Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ofatumumab in multiple sclerosis (MS) and secondary-progressive multiple sclerosis (SPMS), sponsored by Novartis. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 1 more. Started Jul 2021; status: completed.
02
Drugs
ofatumumab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on jRCT2031210175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210175.